 |
PDBsum entry 2axm
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Growth factor
|
PDB id
|
|
|
|
2axm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
393:812-817
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of a heparin-linked biologically active dimer of fibroblast growth factor.
|
|
A.D.DiGabriele,
I.Lax,
D.I.Chen,
C.M.Svahn,
M.Jaye,
J.Schlessinger,
W.A.Hendrickson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The fibroblast growth factors (FGFs) form a large family of structurally
related, multifunctional proteins that regulate various biological responses.
They mediate cellular functions by binding to transmembrane FGF receptors, which
are protein tyrosine kinases. FGF receptors are activated by oligomerization,
and both this activation and FGF-stimulated biological responses require
heparin-like molecules as well as FGF. Heparins are linear anionic
polysaccharide chains; they are typically heterogeneously sulphated on
alternating L-iduronic and D-glucosamino sugars, and are nearly ubiquitous in
animal tissues as heparan sulphate proteoglycans on cell surfaces and in the
extracellular matrix. Although several crystal structures have been described
for FGF molecules in complexes with heparin-like sugars, the nature of a
biologically active complex has been unknown until now. Here we describe the
X-ray crystal structure, at 2.9 A resolution, of a biologically active dimer of
human acidic FGF in a complex with a fully sulphated, homogeneous heparin
decassacharide. The dimerization of heparin-linked acidic FGF observed here is
an elegant mechanism for the modulation of signalling through combinatorial
homodimerization and heterodimerization of the 12 known members of the FGF
family.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2 Structures of heparin-linked aFGF dimers. a, This
sigma-weighted electron-density map at 2.9 Å resolution in the
region of the bound heparin was generated without the
decasaccharide in the model. Blue contour is at 1 and
pink contour is at 4 .
b, A stereo view of heparin-linked dimer A (orthorhombic
asymmetric unit) of human aFGF. The amino and carboxy termini of
the protomers, and the O1 and O4 ends of the sugar, are
labelled. The location of the alpha carbon atom of every tenth
residue is shown by a numbered black circle. c, The
superposition of one aFGF protomer (A1, B3 and C5) (bottom) from
each aFGF dimer in the orthorhombic asymmetric unit, using
program O (ref. 26), shows the variabiity in positions of the
second protomers (A2, blue, B4, cyan, C6, yellow worms; top) and
heparin chains (A[sugar], blue, B[sugar], cyan, C[sugar],
yellow; centre). Protomer A1 is depicted as a blue ribbon
(bottom) showing labelled secondary structure^27. The hexagonal
asymmetric unit (H7, H8 and H[sugar] are not shown) is most
similar to aFGF dimer A. Rotations and translations that
superimpose the second protomers B4, H8 and C6 on A2 are,
respectively, 16.2° and 0.6 Å, 7.5° and 0.4 Å, and 16.8° and 1.5
Å. Prepared with program O (a) and SETOR28 (b, c).
|
 |
Figure 3.
Figure 3 a-d, Details of hydrogen bonding between aFGF
protomers (ribbons) and heparin (ball-and-stick diagrams) in
aFGF dimers. A and C. After C superposition,
protomers of one dimer and bound sugar were placed side by side
for comparison. A1 (a) and C5 (c) bind A[sugar] and C[sugar],
respectively, with 'O1 to O4' polarity. A2 (b) and C6 (d) bind
the corresponding sugars with 'O4 to O1' polarity. All side
chains within 4 Å of the sugar are shown. Atoms are colour-coded
by element (C, white; O, red; S, yellow; N, blue) and
interactions are shown as dashed yellow lines. Monosaccharide
units are labelled as S for N-acetyl glucosamine and I for
iduronic acid. e, Superposition of the six aFGF protomers and
bound heparin chains in the orthorhombic asymmetric unit looking
down on the sugar-binding loop (blue worm segment). Protein side
chains and corresponding sulphate groups (spheres) are a
different colour for each protomer. Three major sulphate-group
binding sites and the amino-acid side chains that form these
sites are shown. f, Electrostatic potential mapped onto the
molecular surface of an aFGF protomer orientated as in e. A
large patch of positive electrostatic potential (blue represents
+10 e per Å) distinguishes the heparin-binding site (heparin is
shown in yellow). g, Surface representation of aFGF dimer A
(Fig. 2b) rotated by 90° about two perpendicular axes. Yellow
surfaces represent FGFR-binding sites. A two-fold axis runs
vertically in the plane of the page between the protomers, such
that the yellow surface at the front of the blue protomer is at
the back of the purple protomer. h, A model for FGFR
dimerization by binding of the extracellular (numbered) FGFR
domains (cyan) to the heparin (orange zigzag)-linked aFGF dimer
(blue and purple circles), orientated as in g. Prepared with
SETOR (a-d, e, g)28 and GRASP (f)29.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(1998,
393,
812-817)
copyright 1998.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.H.Wang,
F.Davamani,
S.C.Sue,
S.C.Lee,
P.L.Wu,
F.M.Tang,
C.Shih,
T.H.Huang,
and
W.G.Wu
(2010).
Cell surface heparan sulfates mediate internalization of the PWWP/HATH domain of HDGF via macropinocytosis to fine-tune cell signalling processes involved in fibroblast cell migration.
|
| |
Biochem J,
433,
127-138.
|
 |
|
|
|
|
 |
J.O'Donnell,
K.A.Taylor,
and
M.S.Chapman
(2009).
Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.
|
| |
Virology,
385,
434-443.
|
 |
|
|
|
|
 |
M.Zakrzewska,
A.Wiedlocha,
A.Szlachcic,
D.Krowarsch,
J.Otlewski,
and
S.Olsnes
(2009).
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.
|
| |
J Biol Chem,
284,
25388-25403.
|
 |
|
|
|
|
 |
K.Tan,
M.Duquette,
J.H.Liu,
K.Shanmugasundaram,
A.Joachimiak,
J.T.Gallagher,
A.C.Rigby,
J.H.Wang,
and
J.Lawler
(2008).
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain.
|
| |
J Biol Chem,
283,
3932-3941.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.S.Gandhi,
and
R.L.Mancera
(2008).
The structure of glycosaminoglycans and their interactions with proteins.
|
| |
Chem Biol Drug Des,
72,
455-482.
|
 |
|
|
|
|
 |
S.J.Goodger,
C.J.Robinson,
K.J.Murphy,
N.Gasiunas,
N.J.Harmer,
T.L.Blundell,
D.A.Pye,
and
J.T.Gallagher
(2008).
Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms.
|
| |
J Biol Chem,
283,
13001-13008.
|
 |
|
|
|
|
 |
C.L.Chaffer,
B.Dopheide,
P.Savagner,
E.W.Thompson,
and
E.D.Williams
(2007).
Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.
|
| |
Differentiation,
75,
831-842.
|
 |
|
|
|
|
 |
C.W.Vander Kooi,
M.A.Jusino,
B.Perman,
D.B.Neau,
H.D.Bellamy,
and
D.J.Leahy
(2007).
Structural basis for ligand and heparin binding to neuropilin B domains.
|
| |
Proc Natl Acad Sci U S A,
104,
6152-6157.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Fan,
H.Li,
M.Zhang,
and
C.R.Middaugh
(2007).
Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1.
|
| |
J Pharm Sci,
96,
1490-1503.
|
 |
|
|
|
|
 |
J.L.de Paz,
C.Noti,
F.Böhm,
S.Werner,
and
P.H.Seeberger
(2007).
Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers.
|
| |
Chem Biol,
14,
879-887.
|
 |
|
|
|
|
 |
N.Kulahin,
V.Kiselyov,
A.Kochoyan,
O.Kristensen,
J.S.Kastrup,
V.Berezin,
E.Bock,
and
M.Gajhede
(2007).
Structure of rat acidic fibroblast growth factor at 1.4 A resolution.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
63,
65-68.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.Raman,
and
R.Sasisekharan
(2007).
Cooperativity in glycan-protein interactions.
|
| |
Chem Biol,
14,
873-874.
|
 |
|
|
|
|
 |
A.Canales,
R.Lozano,
B.López-Méndez,
J.Angulo,
R.Ojeda,
P.M.Nieto,
M.Martín-Lomas,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
|
| |
FEBS J,
273,
4716-4727.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Canales-Mayordomo,
R.Fayos,
J.Angulo,
R.Ojeda,
M.Martín-Pastor,
P.M.Nieto,
M.Martín-Lomas,
R.Lozano,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods.
|
| |
J Biomol NMR,
35,
225-239.
|
 |
|
|
|
|
 |
C.J.Robinson,
B.Mulloy,
J.T.Gallagher,
and
S.E.Stringer
(2006).
VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.
|
| |
J Biol Chem,
281,
1731-1740.
|
 |
|
|
|
|
 |
H.Jenssen,
P.Hamill,
and
R.E.Hancock
(2006).
Peptide antimicrobial agents.
|
| |
Clin Microbiol Rev,
19,
491-511.
|
 |
|
|
|
|
 |
J.Kittiworakarn,
A.Lecoq,
G.Moine,
R.Thai,
E.Lajeunesse,
P.Drevet,
C.Vidaud,
A.Ménez,
and
M.Léonetti
(2006).
HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers.
|
| |
J Biol Chem,
281,
3105-3115.
|
 |
|
|
|
|
 |
L.Zhang,
E.M.Furst,
and
K.L.Kiick
(2006).
Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions.
|
| |
J Control Release,
114,
130-142.
|
 |
|
|
|
|
 |
R.Sasisekharan,
R.Raman,
and
V.Prabhakar
(2006).
Glycomics approach to structure-function relationships of glycosaminoglycans.
|
| |
Annu Rev Biomed Eng,
8,
181-231.
|
 |
|
|
|
|
 |
A.Naggi,
B.Casu,
M.Perez,
G.Torri,
G.Cassinelli,
S.Penco,
C.Pisano,
G.Giannini,
R.Ishai-Michaeli,
and
I.Vlodavsky
(2005).
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
|
| |
J Biol Chem,
280,
12103-12113.
|
 |
|
|
|
|
 |
C.J.Robinson,
N.J.Harmer,
S.J.Goodger,
T.L.Blundell,
and
J.T.Gallagher
(2005).
Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes.
|
| |
J Biol Chem,
280,
42274-42282.
|
 |
|
|
|
|
 |
J.P.Li,
M.L.Galvis,
F.Gong,
X.Zhang,
E.Zcharia,
S.Metzger,
I.Vlodavsky,
R.Kisilevsky,
and
U.Lindahl
(2005).
In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
|
| |
Proc Natl Acad Sci U S A,
102,
6473-6477.
|
 |
|
|
|
|
 |
L.Jin,
P.E.Barran,
J.A.Deakin,
M.Lyon,
and
D.Uhrín
(2005).
Conformation of glycosaminoglycans by ion mobility mass spectrometry and molecular modelling.
|
| |
Phys Chem Chem Phys,
7,
3464-3471.
|
 |
|
|
|
|
 |
M.Mohammadi,
S.K.Olsen,
and
O.A.Ibrahimi
(2005).
Structural basis for fibroblast growth factor receptor activation.
|
| |
Cytokine Growth Factor Rev,
16,
107-137.
|
 |
|
|
|
|
 |
T.C.Aupérin,
G.R.Bolduc,
M.J.Baron,
A.Heroux,
D.J.Filman,
L.C.Madoff,
and
J.M.Hogle
(2005).
Crystal structure of the N-terminal domain of the group B streptococcus alpha C protein.
|
| |
J Biol Chem,
280,
18245-18252.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Angulo,
R.Ojeda,
J.L.de Paz,
R.Lucas,
P.M.Nieto,
R.M.Lozano,
M.Redondo-Horcajo,
G.Giménez-Gallego,
and
M.Martín-Lomas
(2004).
The activation of fibroblast growth factors (FGFs) by glycosaminoglycans: influence of the sulfation pattern on the biological activity of FGF-1.
|
| |
Chembiochem,
5,
55-61.
|
 |
|
|
|
|
 |
J.P.Lai,
J.R.Chien,
D.R.Moser,
J.K.Staub,
I.Aderca,
D.P.Montoya,
T.A.Matthews,
D.M.Nagorney,
J.M.Cunningham,
D.I.Smith,
E.L.Greene,
V.Shridhar,
and
L.R.Roberts
(2004).
hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling.
|
| |
Gastroenterology,
126,
231-248.
|
 |
|
|
|
|
 |
M.J.Bernett,
T.Somasundaram,
and
M.Blaber
(2004).
An atomic resolution structure for human fibroblast growth factor 1.
|
| |
Proteins,
57,
626-634.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.A.Gittens,
K.Bagnall,
J.R.Matyas,
R.Löbenberg,
and
H.Uludag
(2004).
Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates.
|
| |
J Control Release,
98,
255-268.
|
 |
|
|
|
|
 |
S.Ashikari-Hada,
H.Habuchi,
Y.Kariya,
N.Itoh,
A.H.Reddi,
and
K.Kimata
(2004).
Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library.
|
| |
J Biol Chem,
279,
12346-12354.
|
 |
|
|
|
|
 |
Y.Wegrowski,
and
F.X.Maquart
(2004).
Involvement of stromal proteoglycans in tumour progression.
|
| |
Crit Rev Oncol Hematol,
49,
259-268.
|
 |
|
|
|
|
 |
A.Facchiano,
K.Russo,
A.M.Facchiano,
F.De Marchis,
F.Facchiano,
D.Ribatti,
M.S.Aguzzi,
and
M.C.Capogrossi
(2003).
Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties.
|
| |
J Biol Chem,
278,
8751-8760.
|
 |
|
|
|
|
 |
C.Birchmeier,
W.Birchmeier,
E.Gherardi,
and
G.F.Vande Woude
(2003).
Met, metastasis, motility and more.
|
| |
Nat Rev Mol Cell Biol,
4,
915-925.
|
 |
|
|
|
|
 |
C.Fernández-Tornero,
R.M.Lozano,
M.Redondo-Horcajo,
A.M.Gómez,
J.C.López,
E.Quesada,
C.Uriel,
S.Valverde,
P.Cuevas,
A.Romero,
and
G.Giménez-Gallego
(2003).
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate.
|
| |
J Biol Chem,
278,
21774-21781.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.D.Kent,
and
J.A.Bomser
(2003).
Bovine pituitary extract provides remarkable protection against oxidative stress in human prostate epithelial cells.
|
| |
In Vitro Cell Dev Biol Anim,
39,
388-394.
|
 |
|
|
|
|
 |
R.Raman,
G.Venkataraman,
S.Ernst,
V.Sasisekharan,
and
R.Sasisekharan
(2003).
Structural specificity of heparin binding in the fibroblast growth factor family of proteins.
|
| |
Proc Natl Acad Sci U S A,
100,
2357-2362.
|
 |
|
|
|
|
 |
T.S.Udayakumar,
E.L.Bair,
R.B.Nagle,
and
G.T.Bowden
(2003).
Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
|
| |
Mol Carcinog,
38,
70-77.
|
 |
|
|
|
|
 |
Y.Luo,
H.H.Cho,
and
W.L.McKeehan
(2003).
Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF).
|
| |
J Pharm Sci,
92,
2117-2127.
|
 |
|
|
|
|
 |
Z.L.Wu,
L.Zhang,
T.Yabe,
B.Kuberan,
D.L.Beeler,
A.Love,
and
R.D.Rosenberg
(2003).
The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex.
|
| |
J Biol Chem,
278,
17121-17129.
|
 |
|
|
|
|
 |
A.I.Arunkumar,
S.Srisailam,
T.K.Kumar,
K.M.Kathir,
Y.H.Chi,
H.M.Wang,
G.G.Chang,
I.Chiu,
and
C.Yu
(2002).
Structure and stability of an acidic fibroblast growth factor from Notophthalmus viridescens.
|
| |
J Biol Chem,
277,
46424-46432.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.I.Arunkumar,
T.K.Kumar,
K.M.Kathir,
S.Srisailam,
H.M.Wang,
P.S.Leena,
Y.H.Chi,
H.C.Chen,
C.H.Wu,
R.T.Wu,
G.G.Chang,
I.M.Chiu,
and
C.Yu
(2002).
Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity.
|
| |
Protein Sci,
11,
1050-1061.
|
 |
|
|
|
|
 |
B.K.Yeh,
A.V.Eliseenkova,
A.N.Plotnikov,
D.Green,
J.Pinnell,
T.Polat,
A.Gritli-Linde,
R.J.Linhardt,
and
M.Mohammadi
(2002).
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate.
|
| |
Mol Cell Biol,
22,
7184-7192.
|
 |
|
|
|
|
 |
D.Letourneur,
D.Machy,
A.Pellé,
E.Marcon-Bachari,
G.D'Angelo,
M.Vogel,
F.Chaubet,
and
J.B.Michel
(2002).
Heparin and non-heparin-like dextrans differentially modulate endothelial cell proliferation: in vitro evaluation with soluble and crosslinked polysaccharide matrices.
|
| |
J Biomed Mater Res,
60,
94.
|
 |
|
|
|
|
 |
D.McCabe,
T.Cukierman,
and
J.E.Gabay
(2002).
Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity.
|
| |
J Biol Chem,
277,
27477-27488.
|
 |
|
|
|
|
 |
I.Capila,
and
R.J.Linhardt
(2002).
Heparin-protein interactions.
|
| |
Angew Chem Int Ed Engl,
41,
391-412.
|
 |
|
|
|
|
 |
J.Kim,
S.I.Blaber,
and
M.Blaber
(2002).
Alternative type I and I' turn conformations in the beta8/beta9 beta-hairpin of human acidic fibroblast growth factor.
|
| |
Protein Sci,
11,
459-466.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Kreuger,
T.Matsumoto,
M.Vanwildemeersch,
T.Sasaki,
R.Timpl,
L.Claesson-Welsh,
D.Spillmann,
and
U.Lindahl
(2002).
Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.
|
| |
EMBO J,
21,
6303-6311.
|
 |
|
|
|
|
 |
J.M.Trowbridge,
J.A.Rudisill,
D.Ron,
and
R.L.Gallo
(2002).
Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7).
|
| |
J Biol Chem,
277,
42815-42820.
|
 |
|
|
|
|
 |
K.Honke,
and
N.Taniguchi
(2002).
Sulfotransferases and sulfated oligosaccharides.
|
| |
Med Res Rev,
22,
637-654.
|
 |
|
|
|
|
 |
M.Zamai,
C.Hariharan,
D.Pines,
M.Safran,
A.Yayon,
V.R.Caiolfa,
R.Cohen-Luria,
E.Pines,
and
A.H.Parola
(2002).
Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
|
| |
Biophys J,
82,
2652-2664.
|
 |
|
|
|
|
 |
P.Stenlund,
M.J.Lindberg,
and
L.A.Tibell
(2002).
Structural requirements for high-affinity heparin binding: alanine scanning analysis of charged residues in the C-terminal domain of human extracellular superoxide dismutase.
|
| |
Biochemistry,
41,
3168-3175.
|
 |
|
|
|
|
 |
R.Sasisekharan,
Z.Shriver,
G.Venkataraman,
and
U.Narayanasami
(2002).
Roles of heparan-sulphate glycosaminoglycans in cancer.
|
| |
Nat Rev Cancer,
2,
521-528.
|
 |
|
|
|
|
 |
S.M.Prince,
M.Achtman,
and
J.P.Derrick
(2002).
Crystal structure of the OpcA integral membrane adhesin from Neisseria meningitidis.
|
| |
Proc Natl Acad Sci U S A,
99,
3417-3421.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Sachchidanand,
O.Lequin,
D.Staunton,
B.Mulloy,
M.J.Forster,
K.Yoshida,
and
I.D.Campbell
(2002).
Mapping the heparin-binding site on the 13-14F3 fragment of fibronectin.
|
| |
J Biol Chem,
277,
50629-50635.
|
 |
|
|
|
|
 |
A.Avrameas,
L.Gasmi,
and
G.Buttin
(2001).
DNA and heparin alter the internalization process of anti-DNA monoclonal antibodies according to patterns typical of both the charged molecule and the antibody.
|
| |
J Autoimmun,
16,
383-391.
|
 |
|
|
|
|
 |
B.Mulloy,
and
R.J.Linhardt
(2001).
Order out of complexity--protein structures that interact with heparin.
|
| |
Curr Opin Struct Biol,
11,
623-628.
|
 |
|
|
|
|
 |
C.P.Libeu,
S.Lund-Katz,
M.C.Phillips,
S.Wehrli,
M.J.Hernáiz,
I.Capila,
R.J.Linhardt,
R.L.Raffaï,
Y.M.Newhouse,
F.Zhou,
and
K.H.Weisgraber
(2001).
New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E.
|
| |
J Biol Chem,
276,
39138-39144.
|
 |
|
|
|
|
 |
D.Lietha,
D.Y.Chirgadze,
B.Mulloy,
T.L.Blundell,
and
E.Gherardi
(2001).
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.
|
| |
EMBO J,
20,
5543-5555.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.J.Hecht,
R.Adar,
B.Hofmann,
O.Bogin,
H.Weich,
and
A.Yayon
(2001).
Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces.
|
| |
Acta Crystallogr D Biol Crystallogr,
57,
378-384.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.H.Murthy,
S.A.Smith,
V.K.Ganesh,
K.W.Judge,
N.Mullin,
P.N.Barlow,
C.M.Ogata,
and
G.J.Kotwal
(2001).
Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans.
|
| |
Cell,
104,
301-311.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Martin,
C.Blanpain,
P.Garnier,
V.Wittamer,
M.Parmentier,
and
C.Vita
(2001).
Structural and functional analysis of the RANTES-glycosaminoglycans interactions.
|
| |
Biochemistry,
40,
6303-6318.
|
 |
|
|
|
|
 |
L.Pellegrini
(2001).
Role of heparan sulfate in fibroblast growth factor signalling: a structural view.
|
| |
Curr Opin Struct Biol,
11,
629-634.
|
 |
|
|
|
|
 |
S.Ye,
Y.Luo,
W.Lu,
R.B.Jones,
R.J.Linhardt,
I.Capila,
T.Toida,
M.Kan,
H.Pelletier,
and
W.L.McKeehan
(2001).
Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs.
|
| |
Biochemistry,
40,
14429-14439.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
W.Shao,
E.Fernandez,
A.Sachpatzidis,
J.Wilken,
D.A.Thompson,
B.I.Schweitzer,
and
E.Lolis
(2001).
CCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-II based on sequence analysis and its solution structure.
|
| |
Eur J Biochem,
268,
2948-2959.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Yoneda,
M.Asada,
Y.Oda,
M.Suzuki,
and
T.Imamura
(2000).
Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.
|
| |
Nat Biotechnol,
18,
641-644.
|
 |
|
|
|
|
 |
D.J.Stauber,
A.D.DiGabriele,
and
W.A.Hendrickson
(2000).
Structural interactions of fibroblast growth factor receptor with its ligands.
|
| |
Proc Natl Acad Sci U S A,
97,
49-54.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.M.Ornitz
(2000).
FGFs, heparan sulfate and FGFRs: complex interactions essential for development.
|
| |
Bioessays,
22,
108-112.
|
 |
|
|
|
|
 |
H.Habuchi,
M.Tanaka,
O.Habuchi,
K.Yoshida,
H.Suzuki,
K.Ban,
and
K.Kimata
(2000).
The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine.
|
| |
J Biol Chem,
275,
2859-2868.
|
 |
|
|
|
|
 |
M.Guzmán-Casado,
J.M.Sánchez-Ruiz,
M.El Harrous,
G.Giménez-Gallego,
and
A.Parody-Morreale
(2000).
Energetics of myo-inositol hexasulfate binding to human acidic fibroblast growth factor effect of ionic strength and temperature.
|
| |
Eur J Biochem,
267,
3477-3486.
|
 |
|
|
|
|
 |
M.L.Tyan
(2000).
Effects of inositol, LiCl, and heparin on the antibody responses to SRBC by normal and immunodeficient XID mice.
|
| |
Proc Soc Exp Biol Med,
224,
187-190.
|
 |
|
|
|
|
 |
M.Lyon,
G.Rushton,
J.A.Askari,
M.J.Humphries,
and
J.T.Gallagher
(2000).
Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin.
|
| |
J Biol Chem,
275,
4599-4606.
|
 |
|
|
|
|
 |
R.L.Gallo
(2000).
Proteoglycans and cutaneous vascular defense and repair.
|
| |
J Investig Dermatol Symp Proc,
5,
55-60.
|
 |
|
|
|
|
 |
R.Sasisekharan,
and
G.Venkataraman
(2000).
Heparin and heparan sulfate: biosynthesis, structure and function.
|
| |
Curr Opin Chem Biol,
4,
626-631.
|
 |
|
|
|
|
 |
R.van der Voort,
R.M.Keehnen,
E.A.Beuling,
M.Spaargaren,
and
S.T.Pals
(2000).
Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans.
|
| |
J Exp Med,
192,
1115-1124.
|
 |
|
|
|
|
 |
S.Tumova,
A.Woods,
and
J.R.Couchman
(2000).
Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions.
|
| |
Int J Biochem Cell Biol,
32,
269-288.
|
 |
|
|
|
|
 |
T.L.Blundell,
D.F.Burke,
D.Chirgadze,
V.Dhanaraj,
M.Hyvönen,
C.A.Innis,
E.Parisini,
L.Pellegrini,
M.Sayed,
and
B.L.Sibanda
(2000).
Protein-protein interactions in receptor activation and intracellular signalling.
|
| |
Biol Chem,
381,
955-959.
|
 |
|
|
|
|
 |
Y.Liu,
A.J.Chirino,
Z.Misulovin,
C.Leteux,
T.Feizi,
M.C.Nussenzweig,
and
P.J.Bjorkman
(2000).
Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand.
|
| |
J Exp Med,
191,
1105-1116.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Sharma,
J.A.Askari,
M.J.Humphries,
E.Y.Jones,
and
D.I.Stuart
(1999).
Crystal structure of a heparin- and integrin-binding segment of human fibronectin.
|
| |
EMBO J,
18,
1468-1479.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Wettreich,
A.Sebollela,
M.A.Carvalho,
S.P.Azevedo,
R.Borojevic,
S.T.Ferreira,
and
T.Coelho-Sampaio
(1999).
Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans.
|
| |
J Biol Chem,
274,
31468-31475.
|
 |
|
|
|
|
 |
B.Berman,
O.Ostrovsky,
M.Shlissel,
T.Lang,
D.Regan,
I.Vlodavsky,
R.Ishai-Michaeli,
and
D.Ron
(1999).
Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor.
|
| |
J Biol Chem,
274,
36132-36138.
|
 |
|
|
|
|
 |
C.Wiesmann,
and
A.M.de Vos
(1999).
Putting two and two together: crystal structure of the FGF-receptor complex.
|
| |
Structure,
7,
R251-R255.
|
 |
|
|
|
|
 |
D.Mikhailov,
H.C.Young,
R.J.Linhardt,
and
K.H.Mayo
(1999).
Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia.
|
| |
J Biol Chem,
274,
25317-25329.
|
 |
|
|
|
|
 |
E.Hurt-Camejo,
B.Rosengren,
P.Sartipy,
K.Elfsberg,
G.Camejo,
and
L.Svensson
(1999).
CD44, a cell surface chondroitin sulfate proteoglycan, mediates binding of interferon-gamma and some of its biological effects on human vascular smooth muscle cells.
|
| |
J Biol Chem,
274,
18957-18964.
|
 |
|
|
|
|
 |
F.Lustig,
J.Hoebeke,
C.Simonson,
G.Ostergren-Lundén,
G.Bondjers,
U.Rüetchi,
and
G.Fager
(1999).
Processing of PDGF gene products determines interactions with glycosaminoglycans.
|
| |
J Mol Recognit,
12,
112-120.
|
 |
|
|
|
|
 |
G.Venkataraman,
R.Raman,
V.Sasisekharan,
and
R.Sasisekharan
(1999).
Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.
|
| |
Proc Natl Acad Sci U S A,
96,
3658-3663.
|
 |
|
|
|
|
 |
G.Venkataraman,
Z.Shriver,
J.C.Davis,
and
R.Sasisekharan
(1999).
Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.
|
| |
Proc Natl Acad Sci U S A,
96,
1892-1897.
|
 |
|
|
|
|
 |
L.Citores,
J.Wesche,
E.Kolpakova,
and
S.Olsnes
(1999).
Uptake and intracellular transport of acidic fibroblast growth factor: evidence for free and cytoskeleton-anchored fibroblast growth factor receptors.
|
| |
Mol Biol Cell,
10,
3835-3848.
|
 |
|
|
|
|
 |
M.Kan,
X.Wu,
F.Wang,
and
W.L.McKeehan
(1999).
Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase.
|
| |
J Biol Chem,
274,
15947-15952.
|
 |
|
|
|
|
 |
M.T.Huhtala,
O.T.Pentikäinen,
and
M.S.Johnson
(1999).
A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding.
|
| |
Structure,
7,
699-709.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.D.Klein,
M.S.Maliner-Jongewaard,
T.S.Udayakumar,
J.L.Boyd,
R.B.Nagle,
and
G.T.Bowden
(1999).
Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells.
|
| |
Prostate,
41,
215-223.
|
 |
|
|
|
|
 |
R.van der Voort,
T.E.Taher,
V.J.Wielenga,
M.Spaargaren,
R.Prevo,
L.Smit,
G.David,
G.Hartmann,
E.Gherardi,
and
S.T.Pals
(1999).
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.
|
| |
J Biol Chem,
274,
6499-6506.
|
 |
|
|
|
|
 |
S.Vallés,
C.Tsoi,
W.Y.Huang,
D.Wyllie,
F.Carlotti,
J.A.Askari,
M.J.Humphries,
S.K.Dower,
and
E.E.Qwarnström
(1999).
Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex. Regulation by fibronectin attachment.
|
| |
J Biol Chem,
274,
20103-20109.
|
 |
|
|
|
|
 |
T.Sasaki,
H.Larsson,
J.Kreuger,
M.Salmivirta,
L.Claesson-Welsh,
U.Lindahl,
E.Hohenester,
and
R.Timpl
(1999).
Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
|
| |
EMBO J,
18,
6240-6248.
|
 |
|
|
|
|
 |
W.L.McKeehan,
X.Wu,
and
M.Kan
(1999).
Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex.
|
| |
J Biol Chem,
274,
21511-21514.
|
 |
|
|
|
|
 |
Y.Kakuta,
T.Sueyoshi,
M.Negishi,
and
L.C.Pedersen
(1999).
Crystal structure of the sulfotransferase domain of human heparan sulfate N-deacetylase/ N-sulfotransferase 1.
|
| |
J Biol Chem,
274,
10673-10676.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Faham,
R.J.Linhardt,
and
D.C.Rees
(1998).
Diversity does make a difference: fibroblast growth factor-heparin interactions.
|
| |
Curr Opin Struct Biol,
8,
578-586.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |